NET ASSET VALUE – 31 August 2024
On the 31 August 2024 Flerie AB's Net Asset Value (NAV) was SEK 4,360 million and NAV per share was SEK 55.85.
| Allocation of NAV | Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV | |
| Product Development | |||||
| Prokarium | 42% | 473 | 6.06 | 10.9% | |
| Xspray Pharma | 18% | 303 | 3.88 | 7.0% | |
| Xintela | 56% | 205 | 2.63 | 4.7% | |
| Empros Pharma | 79% | 204 | 2.62 | 4.7% | |
| KAHR Medical | 31% | 193 | 2.47 | 4.4% | |
| Atrogi | 37% | 176 | 2.25 | 4.0% | |
| Lipum | 57% | 148 | 1.90 | 3.4% | |
| Microbiotica | 11% | 135 | 1.73 | 3.1% | |
| Mendus | 24% | 103 | 1.32 | 2.4% | |
| Geneos Therapeutics | 12% | 98 | 1.26 | 2.3% | |
| Toleranzia | 58% | 58 | 0.75 | 1.3% | |
| EpiEndo Pharmaceuticals | 9% | 56 | 0.72 | 1.3% | |
| Synerkine Pharma | 43% | 52 | 0.67 | 1.2% | |
| AnaCardio | 19% | 52 | 0.66 | 1.2% | |
| Egetis Therapeutics | 2% | 42 | 0.53 | 1.0% | |
| Buzzard Pharmaceuticals | 14% | 29 | 0.37 | 0.7% | |
| Vitara Biomedical | 5% | 27 | 0.35 | 0.6% | |
| Sixera Pharma | 23% | 26 | 0.33 | 0.6% | |
| Alder Therapeutics | 21% | 17 | 0.22 | 0.4% | |
| Amarna Therapeutics | 60% | 11 | 0.15 | 0.3% | |
| Strike Pharma | 16% | 9 | 0.11 | 0.2% | |
| Total | 2,419 | 30.98 | 55.5% | ||
| Commercial Growth | |||||
| NorthX Biologics | 92% | 189 | 2.42 | 4.3% | |
| Symcel | 31% | 169 | 2.16 | 3.9% | |
| A3P Biomedical | 8% | 75 | 0.96 | 1.7% | |
| Chromafora | 31% | 73 | 0.93 | 1.7% | |
| Provell Pharmaceuticals | 72% | 68 | 0.87 | 1.6% | |
| Nanologica | 39% | 42 | 0.54 | 1.0% | |
| Frontier Biosolutions | 2% | 19 | 0.24 | 0.4% | |
| Bohus Biotech | 45% | 17 | 0.21 | 0.4% | |
| Total | 651 | 8.34 | 14.9% | ||
| Limited Partnerships, total | 87 | 1.11 | 2.0% | ||
| Assets related to portfolio companies | 398 | 5.10 | 9.1% | ||
| Other assets and liabilities | 805 | 10.32 | 18.5% | ||
| NAV | 4 360 | 55.85 | 100.0% | ||
| * indirect shares in Provell Pharmaceuticals | |||||